Table 4 Effective drugs for the reduction of HPRT1
Cell line | Drug | Inhibition target | Target symbol | PTEZ score |
|---|---|---|---|---|
Drugs with significant reduction in HPRT1 expression post treatment | ||||
HT29 | AS-703026 | Mitogen-activated protein kinase | MEK | − 9.822 |
HUES3 | OTS-167 | Maternal embryonic leucine-zipper kinase | MELK | − 9.707 |
Jurkat | BGT-226 | Phosphoinositide 3-kinase | P13K | − 8.533 |
MCF7 | genz-644282 | Topoisomerase I | Topo I | − 7.601 |
A375 | AS-703026 | Mitogen-activated protein kinase | MEK | − 7.119 |
MCF7 | SN-38 | Topoisomerase I | Topo I | − 6.904 |
A375 | SN-38 | Topoisomerase I | Topo I | − 6.702 |
HT29 | TAK-733 | Mitogen-activated protein kinase | MEK | − 6.594 |
MCF7 | Paclitaxel | Microtubule function | – | − 6.537 |
MCF7 | KX2-391 | Sarcome | Src | − 6.366 |
Drugs with an increase in HPRT1 expression post treatment | ||||
MNEU | Dinaciclib | Cyclin dependent kinase | CDK | 2.362 |
NPC | SB-939 | Histone deacetylase | HDAC | 2.39 |
MNEU | Mitoxantrone | Topoisomerase II | Topo II | 2.412 |
NEU | Ischemin | P53 transcription | – | 2.454 |
ASC | Mitoxantrone | Inflammation | – | 2.551 |
NEU | NVP-BGJ398 | Fibroblast growth factor receptor | FGFR | 2.668 |
Jurkat | Tanespimycin | Heat shock protein | HSP | 2.72 |
SKL | Dinaciclib | Cyclin dependent kinase | CDK | 3.137 |
ASC | Dinaciclib | Cyclin dependent kinase | CDK | 3.195 |
Jurkat | Dinaciclib | Cyclin dependent kinase | CDK | 5.414 |